Followers | 183 |
Posts | 25222 |
Boards Moderated | 14 |
Alias Born | 04/03/2002 |
Monday, June 28, 2021 2:34:49 PM
About Inhibikase (http://www.inhibikase.com)
Inhibikase Therapeutics, Inc. (NASDAQ: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Inhibikase's multi-therapeutic pipeline focuses on neurodegeneration and its lead program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to treat Parkinson's disease inside and outside the brain. Inhibikase is currently performing its Phase I, randomized single ascending dose and multiple ascending dose, study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. The Company is also advancing a novel drug delivery platform to treat certain forms of cancer at the same time as it is developing novel drugs for the treatment of neurodegenerative disease. Inhibikase is headquartered in Atlanta, Georgia with offices in Boston, Massachusetts.
Recent IKT News
- Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity • GlobeNewswire Inc. • 08/14/2024 08:25:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:14:00 PM
- Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024 • GlobeNewswire Inc. • 08/07/2024 12:00:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/18/2024 09:23:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/18/2024 09:18:33 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 06/18/2024 09:27:36 PM
- Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease • GlobeNewswire Inc. • 06/17/2024 12:05:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 06/10/2024 08:20:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:05:30 PM
- Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs • GlobeNewswire Inc. • 06/05/2024 12:05:00 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 06/04/2024 08:11:31 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/22/2024 12:55:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 12:55:02 PM
- Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million • GlobeNewswire Inc. • 05/20/2024 12:01:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/20/2024 11:09:42 AM
- Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity • GlobeNewswire Inc. • 05/16/2024 12:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 09:04:56 PM
- Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement • GlobeNewswire Inc. • 05/15/2024 12:45:00 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 05/15/2024 11:56:55 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/09/2024 06:41:37 PM
- Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension • GlobeNewswire Inc. • 05/09/2024 12:00:00 PM
- Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs • GlobeNewswire Inc. • 04/18/2024 08:30:00 PM
- Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension • GlobeNewswire Inc. • 04/03/2024 12:05:00 PM
- Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity • GlobeNewswire Inc. • 03/27/2024 08:15:20 PM
- Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders • GlobeNewswire Inc. • 03/07/2024 01:30:00 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM